Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis

G. Paul Wright, Katherine E. Poruk, Mazen S. Zenati, Jennifer Steve, Nathan Bahary, Melissa E. Hogg, Amer H. Zuriekat, Christopher L. Wolfgang, Herbert J. Zeh, Matthew J. Weiss

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction: Patients with metastatic pancreatic adenocarcinoma have traditionally been offered palliative chemotherapy alone, and the role of surgery in these patients remains unknown. Methods: A bi-institutional retrospective review was performed for patients with metastatic pancreatic adenocarcinoma who underwent resection of the primary tumor from 2008 to 2013. The primary outcome measured was postoperative overall survival. Secondary outcomes included postoperative disease-free survival and overall survival from the time of diagnosis. Results: Twenty-three patients were identified who met the study criteria with a median follow-up of 30 months. Metastatic sites included the liver (n = 16), the lung (n = 6), and the peritoneum (n = 2). Chemotherapy included FOLFIRINOX (n = 14) and gemcitabine-based regimens (n = 9), with a median of 9 cycles (range 2–31) prior to surgical treatment. Median time from diagnosis to surgery was 9.7 months (IQR 5.8–12.8). Median overall survival (OS) from surgery, disease-free survival, and OS from diagnosis were 18.2 months (95 % CI 11.8–35.5), 8.6 months (95 % CI 5.2–16.8), and 34.1 months (95 % CI 22.5–46.2), respectively. The 1- and 3-year OS from surgery were 72.7 % (95 % CI 49.1–86.7) and 21.5 % (95 % CI 4.3–47.2), respectively. Conclusion: Resection of the primary tumor in patients with metastatic pancreatic adenocarcinoma may be considered in highly selected patients with favorable imaging and CA 19-9 response following chemotherapy at high-volume centers providing multidisciplinary care. These patients should be enrolled in prospective clinical trials or institutional registries to better quantify the potential benefits of such a strategy.

Original languageEnglish (US)
Pages (from-to)1830-1835
Number of pages6
JournalJournal of Gastrointestinal Surgery
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

Adenocarcinoma
Neoplasm Metastasis
Drug Therapy
Survival
Neoplasms
gemcitabine
Disease-Free Survival
Peritoneum
Registries
Clinical Trials
Lung
Liver

Keywords

  • Metastasectomy
  • Metastatic
  • Pancreatic cancer

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases : a Bi-institutional Analysis. / Wright, G. Paul; Poruk, Katherine E.; Zenati, Mazen S.; Steve, Jennifer; Bahary, Nathan; Hogg, Melissa E.; Zuriekat, Amer H.; Wolfgang, Christopher L.; Zeh, Herbert J.; Weiss, Matthew J.

In: Journal of Gastrointestinal Surgery, Vol. 20, No. 11, 01.11.2016, p. 1830-1835.

Research output: Contribution to journalArticle

Wright, G. Paul ; Poruk, Katherine E. ; Zenati, Mazen S. ; Steve, Jennifer ; Bahary, Nathan ; Hogg, Melissa E. ; Zuriekat, Amer H. ; Wolfgang, Christopher L. ; Zeh, Herbert J. ; Weiss, Matthew J. / Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases : a Bi-institutional Analysis. In: Journal of Gastrointestinal Surgery. 2016 ; Vol. 20, No. 11. pp. 1830-1835.
@article{d216e9da632146ab931d3a4a3cff8865,
title = "Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis",
abstract = "Introduction: Patients with metastatic pancreatic adenocarcinoma have traditionally been offered palliative chemotherapy alone, and the role of surgery in these patients remains unknown. Methods: A bi-institutional retrospective review was performed for patients with metastatic pancreatic adenocarcinoma who underwent resection of the primary tumor from 2008 to 2013. The primary outcome measured was postoperative overall survival. Secondary outcomes included postoperative disease-free survival and overall survival from the time of diagnosis. Results: Twenty-three patients were identified who met the study criteria with a median follow-up of 30 months. Metastatic sites included the liver (n = 16), the lung (n = 6), and the peritoneum (n = 2). Chemotherapy included FOLFIRINOX (n = 14) and gemcitabine-based regimens (n = 9), with a median of 9 cycles (range 2–31) prior to surgical treatment. Median time from diagnosis to surgery was 9.7 months (IQR 5.8–12.8). Median overall survival (OS) from surgery, disease-free survival, and OS from diagnosis were 18.2 months (95 {\%} CI 11.8–35.5), 8.6 months (95 {\%} CI 5.2–16.8), and 34.1 months (95 {\%} CI 22.5–46.2), respectively. The 1- and 3-year OS from surgery were 72.7 {\%} (95 {\%} CI 49.1–86.7) and 21.5 {\%} (95 {\%} CI 4.3–47.2), respectively. Conclusion: Resection of the primary tumor in patients with metastatic pancreatic adenocarcinoma may be considered in highly selected patients with favorable imaging and CA 19-9 response following chemotherapy at high-volume centers providing multidisciplinary care. These patients should be enrolled in prospective clinical trials or institutional registries to better quantify the potential benefits of such a strategy.",
keywords = "Metastasectomy, Metastatic, Pancreatic cancer",
author = "Wright, {G. Paul} and Poruk, {Katherine E.} and Zenati, {Mazen S.} and Jennifer Steve and Nathan Bahary and Hogg, {Melissa E.} and Zuriekat, {Amer H.} and Wolfgang, {Christopher L.} and Zeh, {Herbert J.} and Weiss, {Matthew J.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1007/s11605-016-3256-2",
language = "English (US)",
volume = "20",
pages = "1830--1835",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases

T2 - a Bi-institutional Analysis

AU - Wright, G. Paul

AU - Poruk, Katherine E.

AU - Zenati, Mazen S.

AU - Steve, Jennifer

AU - Bahary, Nathan

AU - Hogg, Melissa E.

AU - Zuriekat, Amer H.

AU - Wolfgang, Christopher L.

AU - Zeh, Herbert J.

AU - Weiss, Matthew J.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: Patients with metastatic pancreatic adenocarcinoma have traditionally been offered palliative chemotherapy alone, and the role of surgery in these patients remains unknown. Methods: A bi-institutional retrospective review was performed for patients with metastatic pancreatic adenocarcinoma who underwent resection of the primary tumor from 2008 to 2013. The primary outcome measured was postoperative overall survival. Secondary outcomes included postoperative disease-free survival and overall survival from the time of diagnosis. Results: Twenty-three patients were identified who met the study criteria with a median follow-up of 30 months. Metastatic sites included the liver (n = 16), the lung (n = 6), and the peritoneum (n = 2). Chemotherapy included FOLFIRINOX (n = 14) and gemcitabine-based regimens (n = 9), with a median of 9 cycles (range 2–31) prior to surgical treatment. Median time from diagnosis to surgery was 9.7 months (IQR 5.8–12.8). Median overall survival (OS) from surgery, disease-free survival, and OS from diagnosis were 18.2 months (95 % CI 11.8–35.5), 8.6 months (95 % CI 5.2–16.8), and 34.1 months (95 % CI 22.5–46.2), respectively. The 1- and 3-year OS from surgery were 72.7 % (95 % CI 49.1–86.7) and 21.5 % (95 % CI 4.3–47.2), respectively. Conclusion: Resection of the primary tumor in patients with metastatic pancreatic adenocarcinoma may be considered in highly selected patients with favorable imaging and CA 19-9 response following chemotherapy at high-volume centers providing multidisciplinary care. These patients should be enrolled in prospective clinical trials or institutional registries to better quantify the potential benefits of such a strategy.

AB - Introduction: Patients with metastatic pancreatic adenocarcinoma have traditionally been offered palliative chemotherapy alone, and the role of surgery in these patients remains unknown. Methods: A bi-institutional retrospective review was performed for patients with metastatic pancreatic adenocarcinoma who underwent resection of the primary tumor from 2008 to 2013. The primary outcome measured was postoperative overall survival. Secondary outcomes included postoperative disease-free survival and overall survival from the time of diagnosis. Results: Twenty-three patients were identified who met the study criteria with a median follow-up of 30 months. Metastatic sites included the liver (n = 16), the lung (n = 6), and the peritoneum (n = 2). Chemotherapy included FOLFIRINOX (n = 14) and gemcitabine-based regimens (n = 9), with a median of 9 cycles (range 2–31) prior to surgical treatment. Median time from diagnosis to surgery was 9.7 months (IQR 5.8–12.8). Median overall survival (OS) from surgery, disease-free survival, and OS from diagnosis were 18.2 months (95 % CI 11.8–35.5), 8.6 months (95 % CI 5.2–16.8), and 34.1 months (95 % CI 22.5–46.2), respectively. The 1- and 3-year OS from surgery were 72.7 % (95 % CI 49.1–86.7) and 21.5 % (95 % CI 4.3–47.2), respectively. Conclusion: Resection of the primary tumor in patients with metastatic pancreatic adenocarcinoma may be considered in highly selected patients with favorable imaging and CA 19-9 response following chemotherapy at high-volume centers providing multidisciplinary care. These patients should be enrolled in prospective clinical trials or institutional registries to better quantify the potential benefits of such a strategy.

KW - Metastasectomy

KW - Metastatic

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84986316054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986316054&partnerID=8YFLogxK

U2 - 10.1007/s11605-016-3256-2

DO - 10.1007/s11605-016-3256-2

M3 - Article

C2 - 27604886

AN - SCOPUS:84986316054

VL - 20

SP - 1830

EP - 1835

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 11

ER -